Sane R - Search Results

1

Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics.

Cheung KWK, Tang Y, Anders D, Barata T, Scalori A, Agarwal P, Sane R, Cheeti S. Cheung KWK, et al. Among authors: sane r. Pharmaceutics. 2024 Apr 20;16(4):564. doi: 10.3390/pharmaceutics16040564. Pharmaceutics. 2024. PMID: 38675225 Free PMC article.

2

Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer.

Sutaria DS, Rasuo G, Harris A, Johnson R, Miles D, Gallo JD, Sane R. Sutaria DS, et al. Among authors: sane r. Pharmaceutics. 2022 Oct 1;14(10):2101. doi: 10.3390/pharmaceutics14102101. Pharmaceutics. 2022. PMID: 36297536 Free PMC article.

3

Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform.

Uguen M, Hilton M, Farid-Kapadia M, Datye A, Chohan S, Carlucci C, Dixon M, Elze M, Chen Y, Cheung KWK, Sane R, Zheng M, Choi Y. Uguen M, et al. Among authors: sane r. J Biopharm Stat. 2023 Nov 2;33(6):800-811. doi: 10.1080/10543406.2022.2162071. Epub 2023 Jan 13. J Biopharm Stat. 2023. PMID: 36637189 Clinical Trial.

4

Understanding CYP3A4 and P-gp mediated drug-drug interactions through PBPK modeling - Case example of pralsetinib.

Bowman C, Dolton M, Ma F, Cheeti S, Kuruvilla D, Sane R, Kassir N, Chen Y. Bowman C, et al. Among authors: sane r. CPT Pharmacometrics Syst Pharmacol. 2024 Apr;13(4):660-672. doi: 10.1002/psp4.13114. Epub 2024 Mar 13. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38481038 Free PMC article.

5

Impact of P-gp inhibition on systemic exposure of pralsetinib and dosing considerations.

Suchomel J, Agarwal P, Anders D, Hughes K, Tang Y, Sane R, Scalori A, Sharma S, Cheeti S. Suchomel J, et al. Among authors: sane r. Clin Transl Sci. 2024 Jun;17(6):e13818. doi: 10.1111/cts.13818. Clin Transl Sci. 2024. PMID: 38807449 Free PMC article.

6

Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.

Kotani N, Wilkins JJ, Wade JR, Dang S, Sutaria DS, Yoshida K, Sundrani S, Ding H, Garcia J, Hinton H, Sane R, Chanu P. Kotani N, et al. Among authors: sane r. Cancer Chemother Pharmacol. 2022 Dec;90(6):511-521. doi: 10.1007/s00280-022-04488-2. Epub 2022 Oct 28. Cancer Chemother Pharmacol. 2022. PMID: 36305957 Free PMC article.

7

The Absolute Bioavailability and Absorption, Metabolism, and Excretion of Ipatasertib, a Potent and Highly Selective Protein Kinase B (Akt) Inhibitor.

Takahashi RH, Malhi V, Liederer BM, Cho S, Deng Y, Dean B, Nugteren J, Yost E, Al-Sayah MA, Sane R, Kshirsagar S, Ma S, Musib L. Takahashi RH, et al. Among authors: sane r. Drug Metab Dispos. 2023 Oct;51(10):1332-1341. doi: 10.1124/dmd.122.001175. Epub 2023 Jul 31. Drug Metab Dispos. 2023. PMID: 37524543

8

Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).

Garralda E, Oh DY, Italiano A, Bedard PL, Delord JP, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh CS, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho BC, Kim TW, Wu B. Garralda E, et al. Among authors: sane r. J Clin Pharmacol. 2024 May;64(5):544-554. doi: 10.1002/jcph.2397. Epub 2024 Jan 17. J Clin Pharmacol. 2024. PMID: 38105505 Clinical Trial.

9

Risk Factors of Hyperglycemia After Treatment With the AKT Inhibitor Ipatasertib in the Prostate Cancer Setting: A Machine Learning-Based Investigation.

Harun R, Sane R, Yoshida K, Sutaria DS, Jin JY, Lu J. Harun R, et al. Among authors: sane r. JCO Clin Cancer Inform. 2023 Apr;7:e2200168. doi: 10.1200/CCI.22.00168. JCO Clin Cancer Inform. 2023. PMID: 37116107 Free PMC article.

10

Evaluation of Patient-Centric Sample Collection Technologies for Pharmacokinetic Assessment of Large and Small Molecules.

Mandlekar S, Sutaria DS, Yang X, Johnson R, Zou Y, Dean B, Chen L, Sane R, Williams K, Cardenas A, Simon M, Fischer S. Mandlekar S, et al. Among authors: sane r. Clin Pharmacol Ther. 2024 Apr 26. doi: 10.1002/cpt.3272. Online ahead of print. Clin Pharmacol Ther. 2024. PMID: 38671563

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

94 results

Search Page